|Slideshows|October 22, 2016

Psychiatric Fallout From Toxic Exposure

Author(s)James S. Brown, Jr, MD, MPH, MS

A growing body of scientific literature associates psychiatric symptoms with man-made toxic substances and environmental exposure. Practical implications for psychiatrists are discussed in this Special Report collection.

To view the information in PDF format, click here.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

ByGrace Thetford-Harvey, MD,Tessa Manning, MD

December 2nd 2025

Digital Apps for Substance Use Reduction: Discussion With InvestigatorJon-Patrick Allem, PhD

ByJon-Patrick Allem, PhD

November 27th 2025

Stuttering, A Misunderstood Condition: What the Field of Neuropsychiatry Can Do to Help

ByGerald A. Maguire, MD

November 25th 2025

New Drug Application Submitted for Centanafidine for Treatment of ADHD

ByJessica Walters

November 25th 2025

Interrelation of Hormones and Adult ADHD

ByJessica Walters,J.J. Sandra Kooij, MD, PhD

November 25th 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Psychiatric Fallout From Toxic Exposure

Newsletter

Related Content

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

Digital Apps for Substance Use Reduction: Discussion With InvestigatorJon-Patrick Allem, PhD

Stuttering, A Misunderstood Condition: What the Field of Neuropsychiatry Can Do to Help

New Drug Application Submitted for Centanafidine for Treatment of ADHD

Interrelation of Hormones and Adult ADHD

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

What Happened to Psychopathology?

Psychiatry Wrapped 2025: Year in Review